<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00961207</url>
  </required_header>
  <id_info>
    <org_study_id>JHStrogerH09-083</org_study_id>
    <nct_id>NCT00961207</nct_id>
  </id_info>
  <brief_title>Triple Blockade of the Renin Angiotensin Aldosterone System in Diabetic (Type 1&amp;2) Proteinuric Patients</brief_title>
  <official_title>Study of Triple Blockade of the Renin Angiotensin Aldosterone System (RAAS) in Diabetic (Type 1&amp;2) Proteinuric Patients With (ACE-, ARB, DRI)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>John H. Stroger Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>John H. Stroger Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study Hypothesis:

      Reduction in albuminuria has been shown to decrease progression of diabetic

      nephropathy. In diabetic nephropathy patients treated with maximal

      antihypertensive doses with dual RAAS blockade (total daily dose valsartan 320

      mg and either enalapril 40 mg or benazepril 40 mg daily, or losartan 100mg), persistent

      albuminuria reflects further additional RAAS activation. Microvascular renal

      disease due to increased RAAS activation may be more effectively treated with

      triple blockade by the addition of a direct renin inhibitor (DRI) Aliskiren.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Altitude trial which used similar drugs was terminated due to increased ADR.
  </why_stopped>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in albuminuria/proteinuria</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of Triple RAAS inhibition with ACE-I, ARB and DRI</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Microalbuminuria</condition>
  <condition>Macroalbuminuric Diabetic Nephropathy</condition>
  <condition>Diabetes</condition>
  <condition>Proteinuria</condition>
  <condition>Albuminuria</condition>
  <arm_group>
    <arm_group_label>Aliskiren in Macroalbuminuria</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Aliskiren 150 mg daily for 2 weeks and then increased to 300 mg daily for 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aliskiren Microalbuminuria</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Aliskiren 150 mg daily for 2 weeks and then increased to 300mg daily for 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aliskiren</intervention_name>
    <description>Aliskiren 150mg daily for 2 weeks and increased to 300 mg daily for 4 weeks.</description>
    <arm_group_label>Aliskiren in Macroalbuminuria</arm_group_label>
    <other_name>Tekturna</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aliskiren</intervention_name>
    <description>Aliskiren 150mg daily for 2 weeks and increased to 300 mg daily for 4 weeks.</description>
    <arm_group_label>Aliskiren Microalbuminuria</arm_group_label>
    <other_name>Tekturna</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Macroalbuminuria &gt; 300mg/g

          -  Microalbuminuria 30-300mg/g

          -  Stable on max dose of an ACE-I or ARB (Can also be titrated to max dosage of ACE-I and
             ARB and stable on those doses for at least 2 weeks)

          -  Blood pressure &lt;130/80 mm Hg at time of enrollment

          -  Diabetic either Type 1 or 2

        Exclusion Criteria:

          -  GFR &lt;60 m/min

          -  Potassium &gt; 5mg/dl at time of enrollment

          -  Pregnant

          -  History of Angioedema

          -  ACE-I cough

          -  Allergic to ARB, ACE-I, DRI

          -  A1C &gt; 9%
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pete Antonopoulos, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>John H. Stroger Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>John H Stroger Hospital of Cook County</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 17, 2009</study_first_submitted>
  <study_first_submitted_qc>August 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 18, 2009</study_first_posted>
  <last_update_submitted>October 24, 2013</last_update_submitted>
  <last_update_submitted_qc>October 24, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 28, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>John H. Stroger Hospital</investigator_affiliation>
    <investigator_full_name>Pete Antonopoulos</investigator_full_name>
    <investigator_title>Clinical Pharmacist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetic Nephropathies</mesh_term>
    <mesh_term>Proteinuria</mesh_term>
    <mesh_term>Albuminuria</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>March 17, 2014</submitted>
    <returned>April 18, 2014</returned>
    <submitted>February 2, 2015</submitted>
    <returned>February 4, 2015</returned>
    <submitted>February 25, 2016</submitted>
    <returned>March 25, 2016</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

